ArticleCancer medicine2022
Comparative effectiveness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this Network Meta-analysis was to compare the current radiotherapy regimens of limited-stage small cell lung cancer (LS-SCLC), in terms of overall survival (OS), progression-free survival (PFS), and the incidence of acute radioactive esophagitis and radioactive pneumonia.
methodsPubMed, Embase, Web of Science, and the Cochrane Library were comprehensively searched until January 2022. The studies were included, comparing radiotherapy regimens in LS-SCLC patients. We compared hypofractionated radiotherapy (HypoTRT), hyperfractionated radiotherapy (HyperTRT), and conventionally fractionated radiotherapy (ConvTRT1(<60 Gy), ConvTRT2(≥60 Gy)).
resultsThere was similar efficacy among the contemporary radiotherapy regimens for PFS of LS-SCLC. HypoTRT and HyperTRT significantly improved the OS of LS-SCLC compared with ConvTRT1 (<60 Gy), while not improving the OS of LS-SCLC compared with ConvTRT2 (≥60 Gy). There was no significant difference between HypoTRT and HyperTRT, between ConvTRT1(<60 Gy) and ConvTRT2(≥60 Gy), respectively. HyperTRT developed the highest odds of acute radioactive esophagitis compared to ConvTRT1(<60 Gy) and ConvTRT2(≥60 Gy). There was no significant difference in the incidence of acute radioactive esophagitis between HypoTRT and HyperTRT, ConvTRT1(<60 Gy), ConvTRT2(≥60 Gy), respectively and between ConvTRT1 and ConvTRT2. There was no statistically significant difference among radiotherapy regimens for the incidence of acute radioactive pneumonia.
conclusionThe current radiotherapy regimens are similar in efficacy and toxicity for LS-SCLC, except for ConvTRT1(<60 Gy). Given the lower costs and convenient logistics management of HypoTRT comparatively, it is an acceptable alternative for LS-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.